The five stocks in today's table are all rated hold with three overvalued by more than 20%. Four have double-digit gains of 13.0% to 85.7% over the last 12 months. With hold ratings these stocks can be up or down by 5.0% over the next 12 months. Four out of five are trading above their 200-day SMA reflecting the risk of a reversion to the mean.
Merck (MRK - Get Report) ($48.17) set a multi-year high at $50.16 on June 4 then as low as $46.03 on July 2. My annual value level is $46.99 with a quarterly pivot at $47.75 and semiannual risky level at $51.80.(PFE - Get Report) ($29.19) set a multi-year high at $31.15 on April 23 then traded as low as $27.12 on June 3. My semiannual value level is $28.62 with a monthly risky level at $29.76. (X - Get Report) ($18.77) set its 2013 high at $26.29 on Jan. 3 and its 2013 low at $15.80 on April 22. My weekly value level is $17.13 with a monthly risky level at $19.31. At the time of publication the author held no positions in any of the stocks mentioned. Follow @Suttmeier This article is commentary by an independent contributor, separate from TheStreet's regular news coverage.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts